Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cambrex Karlskoga, a subsidiary of Cambrex Corporation, has entered into a purchase agreement for all of the stock of ProSyntest, an active pharmaceutical ingredients R&D company.
Subscribe to our email newsletter
The business will be renamed Cambrex Tallinn after completion of the acquisition. Cambrex intends to add more process and analytical chemists at the site and continue early active pharmaceutical ingredients development work in Tallinn for scale up at Karlskoga and the other Cambrex manufacturing facilities.
Steven Klosk, executive vice president and COO of Cambrex Corporation, said: “Cambrex Karlskoga has successfully worked with the ProSyntest chemists for the past 15 years, and the acquisition of the business is a natural extension of our long-standing relationship. ProSyntest, located in eastern Europe, will enable Cambrex to more effectively compete in the high-growth early clinical stage pharmaceutical custom development market and provide us with a strong pool of talented chemists to advance numerous proprietary strategic initiatives.”